Search results for "β2-agonist"
showing 5 items of 5 documents
Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study.
2015
Background: Pregnant women with asthma need to take medication during pregnancy.Objective: We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy.Methods: We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 reg…
Analysis of β2-agonists in cattle hair samples using a rapid UHPLC–ESI–MS/MS method
2016
A simple and efficient method was developed for simultaneous analysis of five illegal residual β2-agonists in cattle hair. β2-Agonists were quantified by ultra high performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry operating in positive multiple-reaction monitoring mode. The method was validated as quantitative confirmatory method according to the EU Decision 2002/657/EC: instrumental linearity, specificity, precision, recovery, decision limit (CCα) and detection capability (CCβ) were evaluated. The recovery were greater than 90% and the method appeared suitable for the control of these β2-agonists in cattle hair samples with LOQ values between …
Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma.
2022
Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, …
Atklāts, krustota dizaina ultra-ilgstošas darbības β2-agonista olodaterola un īsas darbības β2-agonista salbutamola bronhodilatējošas ietekmes ātruma…
2018
Astmai un hroniskai obstruktīvai plaušu slimībai (HOPS) ir liela socio-ekonomiska ietekme uz sabiedrīebu un tās ir vienas no galvenajiem saslimstības un mirstības cēloņiem pasaulē. Šo obstruktīvo plaušu slimību ārstēšana balstās uz β2-agonistu un citu zāļu bronhodilatatora iedarbību. Lai salīdzinātu ilgstošas-darbības β2-agonista olodaterola bronhodilatācijas efektu ar īslaicīgas-darbības β2-agonistu salbutamolu tika veikts atklāto pārbaužu eksperimentāls pētījums, kurā piedalījās 10 pacienti ar HOPS vai astmu, un tika noteikts abu zāļu bronhodilatācijas efekts, izmantojot FEV1 kā galveno parametru. Tika veikti ķermeņa plejismogrāfijas izmeklējumi, kuru laikā nolasīja sākumpunkta vērtību. 5…
Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…
2014
Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…